ImmuPharma plc (LON:IMM – Get Free Report) was down 8.9% during trading on Thursday . The company traded as low as GBX 3.33 and last traded at GBX 3.33. Approximately 1,838,091 shares traded hands during mid-day trading, a decline of 36% from the average daily volume of 2,850,241 shares. The stock had previously closed at GBX 3.65.
ImmuPharma Price Performance
The firm has a 50 day simple moving average of GBX 4.27 and a two-hundred day simple moving average of GBX 5.58. The stock has a market cap of £21.68 million, a price-to-earnings ratio of -9.39 and a beta of 3.00.
ImmuPharma (LON:IMM – Get Free Report) last posted its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 1,397.44% and a net margin of 3,519.56%. On average, sell-side analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- MarketBeat Week in Review – 06/29 – 07/03
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
